Publication Name	World Journal of Diabetes
Manuscript ID	97795
Country	India

Received	2024-06-08 17:23
Peer-Review Started	2024-06-08 17:23
To Make the First Decision
Return for Revision	2024-07-19 03:18
Revised	2024-07-23 16:13
Second Decision	2024-07-26 02:33
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-07-26 09:07
Articles in Press	2024-07-26 09:07
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-08-03 13:11
Typeset the Manuscript	2024-08-31 21:01
Publish the Manuscript Online	2024-09-26 08:51

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Editorial
Article Title	Immunotherapy in type 1 diabetes: Novel pathway to the future ahead
Manuscript Source	Invited Manuscript
All Author List	Sayantan Ray and Rajan Palui
ORCID	Author(s) ORCID Number Sayantan Ray http://orcid.org/0000-0002-6274-465X Rajan Palui http://orcid.org/0000-0002-2429-3595
Funding Agency and Grant Number
Corresponding Author	Rajan Palui, DM, MBBS, MD, Manager, Department of Endocrinology, The Mission Hospital, Bidhannagar, Durgapur 713212, India. rajanpalui@gmail.com
Key Words	Type 1 diabetes; Immunotherapy; Teplizumab; Antigen based therapy; Stem cell immunotherapy
Core Tip	There has been a paradigm shift in the research on type 1 diabetes (T1D) in the last decade. From managing the consequences of β cell death to prevention of β cell destruction, immunotherapy is showing the path forward. Recent regulatory approval of teplizumab in stage 2 of T1D marks the first significant milestone of advancement in the research of immunotherapy. In this editorial, we briefly explored the recent developments and prospects in the field of immunotherapy in T1D encompassing antibody-based therapy, antigen-based therapy, and stem-cell-based immunotherapy.
Publish Date	2024-09-26 08:51
Citation	<p>Ray S, Palui R. Immunotherapy in type 1 diabetes: Novel pathway to the future ahead. <i>World J Diabetes</i> 2024; 15(10): 2022-2035</p>
URL	https://www.wjgnet.com/1948-9358/full/v15/i10/2022.htm
DOI	https://dx.doi.org/10.4239/wjd.v15.i10.2022

Full Article (PDF)	WJD-15-2022-with-cover.pdf
Manuscript File	97795_Auto_Edited_062910.docx
Answering Reviewers	97795-answering-reviewers.pdf
Audio Core Tip	97795-audio.m4a
Conflict-of-Interest Disclosure Form	97795-conflict-of-interest-statement.pdf
Copyright License Agreement	97795-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	97795-non-native-speakers.pdf
Peer-review Report	97795-peer-reviews.pdf
Scientific Misconduct Check	97795-scientific-misconduct-check.png
Scientific Editor Work List	97795-scientific-editor-work-list.pdf
CrossCheck Report	97795-crosscheck-report.pdf